NASDAQ$DNTH
Dianthus Therapeutics Inc · Q1 2025 earnings
Q1 2025 earnings ·
Briefing
DNTH Q1 2025 — $1.0M revenue, 35.00 EPS
DNTH103 or any other product candidate, our anticipated preclinical and clinical drug development activities, in particular with respect to DNTH103, and any timelines, developments or results in conne. Dianthus Therapeutics Inc reported Q1 2025 results. Diluted EPS came in at $35.00. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $1.0M.
- Diluted EPS: $35.00.
- Operating income: $33K.
Headline financials
Revenue & EPS history
Dianthus Therapeutics Inc · Revenue · Quarterly
$1.16M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q1 2025
+1.6%
Avg return
Earnings day
-2.3%
Avg return
5 days after
+1.9%
Avg return
30 days after
73%
11 / 15 earnings
Positive
+11.1%
Q2 2019
Best reaction
-6.1%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.1% | -2.9% | -5.8% | |
| Q4 2025 | +9.7% | -1.7% | +15.7% | |
| Q3 2025 | +1.6% | +10.3% | +33.3% | |
| Q2 2025 | -6.1% | -2.4% | +30.0% | |
| Q1 2025 | +2.5% | +0.5% | -7.5% | |
| Q3 2023 | +0.4% | -0.5% | -16.4% | |
| Q2 2023 | +2.5% | -1.2% | -8.6% | |
| Q3 2020 | -0.9% | -1.4% | +11.7% | |
| Q2 2020 | +0.6% | +0.0% | -8.3% | |
| Q1 2020 | +2.7% | -1.3% | +5.4% | |
| Q3 2019 | -2.2% | -13.5% | +21.2% | |
| Q2 2019 | +11.1% | -0.8% | -13.2% | |
| Q1 2019 | +2.7% | +9.9% | -10.7% | |
| Q3 2018 | -3.4% | -24.7% | -14.1% | |
| Q2 2018 | +1.2% | -4.2% | -4.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro